biotech / news / / Seeking Alpha
Novo Nordisk is losing GLP-1 and diabetes market share in key regions.
Novo Nordisk is losing U.S. diabetes and obesity market share to Eli Lilly's Zepbound and Mounjaro.
KEY POINTS
- Novo Nordisk's latest GLP-1 drug showed weaker weight loss efficacy than Eli Lilly's offerings.
- Semaglutide patents are expiring in key international markets, opening the door to cheaper generics.
- Intensifying competition and drug pricing regulations are negatively impacting Novo Nordisk's profit margins.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →